Background {#Sec1}
==========

Appropriate supportive care is critical for effective and safe cancer chemotherapy. In particular, febrile neutropenia (FN) is an adverse drug reaction associated with cancer chemotherapy \[[@CR1]\] that may decrease patient quality of life (QOL) due to hospitalization or prolongation of the length of hospital stay, attenuated therapeutic efficacy due to a reduction in the relative dose intensity (RDI), impact on prognosis, and increased treatment-related mortality \[[@CR2]\]. Thus, appropriate supportive care for FN is required. Clinical practice guidelines for granulocyte-colony stimulating factors (G*-*CSFs) are published by the American Society of Clinical Oncology (ASCO) \[[@CR3], [@CR4]\], the National Comprehensive Cancer Network (NCCN) (<http://www.nccn.org>/), and the European Organization for Research and Treatment of Cancer (EORTC) \[[@CR5]\]. The clinical practice guidelines for the appropriate use of G-CSFs published by the Japan Society of Clinical Oncology (JSCO) in 2001 were based on the guideline requirements according to the actual situation in Japan. The guidelines were updated to version 2 in 2013 (<http://jsco-cpg.jp/item/30/index.html>). They recommend the use of G-CSFs based on the risk of the cancer chemotherapy regimen.

The Appraisal of Guidelines for Research and Evaluation (AGREE) ([http://www.agreetrust.org/agree-ii/](http://www.agreetrust.org/agree-ii)), which provides guidance for preparing guidelines, state that guidelines should be user-friendly, and that routine confirmation of the penetration rate and compliance are important. However, it is often unknown how guidelines are actually used in clinical practice and the accessibility, penetration rate, and compliance regarding the current JSCO guidelines have not been well assessed.

Managing FN that accompanies the use of anti-cancer drugs is important for the best practice of cancer pharmacotherapy; it is critical to assemble a team of medical care providers comprising physicians, pharmacists, and nurses. Among these team members, pharmacists play a role in providing proper cancer pharmacotherapy based on their pharmacological knowledge of general drugs, in addition to providing pharmacotherapy for cancer treatment. Therefore, we conducted a nationwide questionnaire survey among pharmacists mainly involved in cancer treatments in order to assess the penetration rate and compliance with the current guidelines in Japanese clinical practice.

Methods {#Sec2}
=======

The questionnaire survey was conducted among Japanese Society of Pharmaceutical (JSPHCS)-certified oncology pharmacists (JOP), JSPHCS-certified senior oncology pharmacists (JSOP), accredited pharmacists of ambulatory cancer chemotherapy (APACC), Japanese Society of Pharmaceutical Oncology (JSPO), board-certified pharmacists in oncology pharmacy (POP), Japanese Society of Hospital Pharmacists (JSHP), board-certified pharmacists in palliative pharmacy (BCPPP), Japanese Society for Pharmaceutical Palliative Care and Sciences (JPPS), and JSCO pharmacists. We requested that they participate in this survey via e-mail. Because the members of JSHP could answer the questionnaire through a link to the members-only website, we requested that respondents who belonged to more than one society to answer through only one of them. By answering the questionnaire, the respondents were considered to have agreed to participate in this research and to agree with the publication of papers. The questionnaires were collected and counted by the JSCO administrative office and the resulting data were analyzed by researchers. This questionnaire survey-based study did not include any health care interventions. Therefore, we did not register the study protocol.

The web-based questionnaire survey was conducted for 14 days between August 24 and September 6, 2015. Text Mining Studio version 5.2 (Mathematical Systems Inc., Tokyo, Japan) was used for the analysis of the descriptions in the free description field.

Results {#Sec3}
=======

Respondent backgrounds {#Sec4}
----------------------

Answers were obtained from 301 respondents (Table [1](#Tab1){ref-type="table"}). Among them, 96.0% (*n* = 289) were hospital pharmacists and had high-level qualifications in oncology, including board-certified POP (*n* = 133) and BCPPP (*n* = 78). Regarding the question on clinical experience, 51.8% (*n* = 156) answered "11 to 20 years", followed by 25.9% (n = 78) who indicated "5 to 10 years". Moreover, 61.5% (*n* = 185) of pharmacists were working at designated cancer care hospitals and 81.7% (*n* = 246) belonged to hospitals with more than 200 beds.Table 1Background of respondents*n* = 301Q1. Which Medical institution do you belong to? Hospital289 (96.0)^a^ Clinic2 (0.7) Pharmacy6 (2.0) Others4 (1.3)Q2. Do you have any certified in society (multiple choice)? JOP69 (22.9) JSOP39 (13.0) POP133 (44.2) APACC43 (14.3) BCPPP78 (25.9) None53 (17.6)Q3. How many duty career of clinical (year) do you have? ≦513 (4.3) 5--1078 (25.9) 11--20156 (51.8) 21--3045 (15.0) ≧319 (3.0)Q4. Was your medical institution designated Regional Cancer Centers and Hospitals? Yes185 (61.5) No116 (38.5)Q5. How many hospital beds does your medical institution have? None7 (2.3) \< 202 (0.7) 20--20027 (9.0) 201--500122 (40.5) 501--1000124 (41.2) ≧100119 (6.3)*JOP* JSPHCS-certified Oncology Pharmacist, *JSOP* JSPHCS-certified Senior Oncology Pharmacist, *POP* Board Certified Pharmacist in Oncology Pharmacy, *APACC* Accredited Pharmacist of Ambulatory Cancer Chemotherapy, *BCPPP* Board Certified Pharmacist in Palliative Pharmacy^a^Number (percent)

Use of the G-CSF guidelines in the daily work of pharmacists {#Sec5}
------------------------------------------------------------

Regarding the question "what do you use as a reference for the use of G-CSFs in clinical practice?", the most frequent answer was "Clinical practice guideline" (*n* = 292) followed by "package insert of G-CSFs" (*n* = 191) (Table [2](#Tab2){ref-type="table"}). In addition, regarding the question "how much importance do you give to the guidelines for the use of G-CSFs in clinical practice?", the most frequent answer (62.1%, *n* = 187) was "give some important", followed by "a high level of importance" (30.6%, *n* = 92) (Table [2](#Tab2){ref-type="table"}). Finally, for the question "when you use the guideline for the use of G-CSF, do you use the Japanese or foreign guidelines?", "Japanese guidelines" was the most frequent response (76.0%, *n* = 229), followed by "Japanese and foreign guidelines" (22.3%, *n* = 67) (Table [2](#Tab2){ref-type="table"}).Table 2Use of the G-CSF guidelines in the daily work of pharmacists*n* = 301Q6. What do you use as a reference for the use of G-CSFs in clinical practice?(multiple choice) Clinical practice guideline292 (97.0)^a^ Guideline of ASCO101 (33.6) Guideline of ERTC11 (3.7) Guideline of NCCN95 (31.6) Package insert191 (63.5)Q7. How much importance do you give to the guideline for the use of G-CSFs in clinical practice? A high level of importance92 (30.6) Give some importance187 (62.1) Do not give importance much22 (7.3) Do not give importance at all0 (0.0)Q8. Do you use the Japanese or foreign guidelines? Japanese guidelines229 (76.0) Foreign guidelines3 (1.0) Japanese and foreign guidelines67 (22.3) Neither2 (0.7)*G-CSF* Granulocyte-Colony Stimulating Factor, *NCCN* National Comprehensive Cancer Network, *EORTC* European Organisation for Research and Treatment of Cancer, *ASCO* American Society of Clinical Oncology^a^Number (percent)

Use of the 2013 guidelines for the appropriate use of G-CSFs, version 2, published by the JSCO {#Sec6}
----------------------------------------------------------------------------------------------

In response to the question "do you know that the JSCO guidelines are available on the web?", 75.7% answered "Yes"; the most frequent response to "how did you learn that the JSCO guidelines are available on a web?" was at an "academic meeting, study group meeting, workshop" (*n* = 182), followed by "website" (*n* = 124) (Table [3](#Tab3){ref-type="table"}). Regarding the question "are the JSCO guidelines useful for the work of pharmacists?", 55.8% (*n* = 168) answered "very useful," and to the question "how often do you refer to the JSCO guidelines?", the most frequent response was "sometimes" (43.5%, *n* = 131) (Table [3](#Tab3){ref-type="table"}). In response to the question "are there any differences between the JSCO guidelines and the actual work of pharmacists?", "somewhat different" was the most frequent response (53.8%, *n* = 162) followed by "not at all" (41.6%, *n* = 125). However, more than half of the respondents (58.4%) answered that "there are differences from the work of pharmacists" (Table [3](#Tab3){ref-type="table"}). These differences were classified as shown in Table [3](#Tab3){ref-type="table"}. For classification, the results of subgraph detection through co-occurrence network analysis in text mining was used as a reference (data not shown). As a result of this classification, "usage of prophylactic administration of G-CSFs" was the most frequent response (7.6%, *n* = 23), followed by "a pharmacist is not involved in the administration of G-CSFs" (6.3%, *n* = 19).Table 3Use of the 2013 guidelines for the appropriate use of G-CSFs, version 2, published by the JSCO*n* = 301Q9. Do you know the JSCO guidelines are available on the web? Yes228 (75.7)^a^ No73 (24.3)Q10. How did you learn that the JSCO guidelines are available on a web? (multiple choice) Academic meeting, study group meeting, workshop182 (60.5) Medical personnel118 (39.2) Academic journal, article21 (7.0) Website124 (41.2) Drug industry44 (14.6) Others3 (1.0)Q11. Are the JSCO guidelines useful for the actual work of pharmacists? Very useful168 (55.8) Useful to some extent127 (42.2) Not so useful6 (2.0) Useless0 (0.0)Q12. How often do you refer to the JSCO guidelines? Always34 (11.3) Usually121 (40.2) Sometimes131 (43.5) Seldom15 (5.0)Q13. Is there any difference between JSCO guideline and the actual work of pharmacists? Not at all125 (41.6) Somewhat different162 (53.8) Considerably difference13 (4.3) Completely different1 (0.3)Q14. To the Q13. which chose "it is totally considerably slightly different with the difference with the difference" by a question. What kind of difference was it? Usage of the prophylaxic administration of G-CSFs23 A pharmacist is not involved in the administration of G-CSFs19 It is difficult to fit a real patient15 Usage of no exothermicity neutropenia11 There is not consensus in the nosocomial G-CSFs usage9 The update of guidelines is late5 It is different from the usage of the package insert5 About the risk classification of the cancer chemotherapy regimen4 Usage of the remedial dosage4 Others11*JSCO* Japan Society of Clinical Oncology, *G-CSF* Granulocyte-Colony Stimulating Factor^a^Number (percent)

Suggestion for the use of G-CSFs in individual cases {#Sec7}
----------------------------------------------------

For cancer chemotherapy regimens with a combination therapy of docetaxel and cyclophosphamide (TC therapy) for the treatment of breast cancer, with an FN incidence \> 20%, the respondents were likely to suggest the primary prophylactic administration of G-CSFs ("I recommend of primary prophylactic administration of G-CSFs": 29.7%) (Table [4](#Tab4){ref-type="table"}). However, when a combination therapy of cisplatin and tegafur/gimeracil/oteracil (S-1) was used for the treatment of advanced and recurrent gastric cancer and a combination therapy of irinotecan, oxaliplatin, and 5-fluorouracil (FOLFOXIRI) was used for the treatment of advanced and recurrent colorectal cancer, with an FN incidence of below 20%, the respondents were unlikely to suggest the primary prophylactic administration of G-CSFs ("I recommend of primary prophylactic administration of G-CSFs": 0.5% and 12.6%, respectively) (Table [4](#Tab4){ref-type="table"}). Regarding the suggestion for the secondary prophylactic administration of G-CSFs for squamous cell lung cancer patients treated with docetaxel alone, 43.4% and 39.3% of the respondents indicated "I use" and "I do not use", respectively (Table [5](#Tab5){ref-type="table"}).Table 4Suggestion for the use of G-CSFs in individual cases. Primary prevention dosage of G-CSFsQ16. TC for breast cancer^a^Q17. CDDP + S-1 for gastric cancer^b^Q18. FOLFOXIRI for colorectal cancer^c^*n* = 145*n* = 187*n* = 183I recommend of primary prophylactic administration of G-CSFs43 (29.7)^d^1 (0.5)23 (12.6)After Grade 4 neutropenia developed, I recommend G-CSFs48 (33.1)63 (33.7)70 (38.2)After FN developed, I recommend G-CSFs54 (37.2)66 (35.3)56 (30.6)I do not recommend G-CSFs0 (0.0)57 (30.5)34 (18.6)*TC* Docetaxel and Cyclophosphamide, *CDDP* Cisplatin, *S-1* Tegafur, gimeracil, and oteracil, *FOLFOXIRI* Irinotecan, oxaliplatin, and 5-fluorouracil, G-*CSF* Granulocyte-Colony Stimulating Factor, *FN* Febrile Neutropenia^a^A 67-year-old woman. You plan to treat with TC therapy (docetaxel 75 mg / m^2^ and cyclophosphamide 600 mg / m^2^, administered every 3 weeks) as postoperative chemotherapy for breast cancer. What kind of suggestion do you do as a pharmacist?^b^A 70-year-old man. As first-line chemotherapy for unresectable gastric cancer, you plan to treat with S-1 and cisplatin combination therapy. What kind of suggestion do you do as a pharmacist?^c^A 70-year-old woman. You plan to treat with irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) therapy as first-line chemotherapy for unresectable colon cancer. What kind of suggestion do you do as a pharmacist?^d^Number (percent)Table 5Suggestion for the use of G-CSFs in individual cases. Secondary prevention dosage of G-CSFsQ15. DTX for squamous cell lung cancer^a^*n* = 168I recommend of secondary prophylactic administration of G-CSFs73 (43.4)^b^After Grade 4 neutropenia developed, I recommend G-CSFs23 (13.7)After FN developed, I recommend G-CSFs6 (3.6)I do not recommend G-CSFs66 (39.3)*DTX* Docetaxel, *G-CSF* Granulocyte-Colony Stimulating Factor, *FN* Febrile Neutropenia^a^A 78-year-old man. You diagnosis of lung squamous cell carcinoma and started docetaxel alone therapy, but complication of febrile neutropenia was appeared. You confirmed a good tumor reduction effect, so you plan to treat the second course. What kind of suggestion do you do as a pharmacist?^b^Number (percent)

Regarding the usage of G-CSF during concurrent chemoradiotherapy (cisplatin 40 mg/m^2^ on days 1, 8, 15, 22, 29, and 36) in patients with stage IIB cervical cancer, "use of G-CSFs is suggested only for high-risk patients" was the most frequent response (30.7%, *n* = 35) (Table [6](#Tab6){ref-type="table"}).Table 6Suggestion for the use of G-CSFs in individual cases. Usage of the GCSFs preparation for cervical cancerQ19. CCRT for cervical cancer^a^*n* = 114I recommend G-CSFs on the following day of chemotherapy6 (5.2)^b^After Grade 4 neutropenia developed, I recommend G-CSFs23 (20.2)After FN developed, I recommend G-CSFs26 (22.8)I recommend G-CSFs to only high risk patients (Less than neutrophilic 100/mm^3^continues more than 10 days and/or fungal infectious disease)35 (30.7)I do not recommend G-CSFs24 (21.1)*CCRT* Concurrent Chemoradiotherapy, *G-CSF* Granulocyte-Colony Stimulating Factor, *FN* Febrile Neutropenia^a^A 30-year-old woman. We plan to concurrent chemoradiotherapy (cisplatin 40 mg/m^2^ on days 1, 8, 15, 22, 29, and 36) in patients with stage IIB cervical cancer (squamous cell carcinoma)^b^Number (percent)

Prophylactic administration and adverse drug reactions to G-CSFs {#Sec8}
----------------------------------------------------------------

Regarding the use of pegfilgrastim during 2-week interval chemotherapy, "I suggest that pegfilgrastim be used on the following day of chemotherapy and on the following day of chemotherapy in the next cycle" was the most frequent response (56.7%, *n* = 93) (Table [7](#Tab7){ref-type="table"}). In response to the question "is G-CSF used as primary prophylaxis at your institute?", 55.3% (*n* = 162) indicated that "G-CSF is used as primary prophylaxis only during chemotherapy aimed at achieving a cure or prolonging survival time" (Table [7](#Tab7){ref-type="table"}).Table 7Prophylactic administration and adverse drug reactions to G-CSFsQ20. Regarding the use of pegfilgrastim during 2-week interval chemotherapy, what kind of suggestion do you do? (*N* = 164) Use pegfilgrastim on the day of chemotherapy2 (1.2) Use pegfilgrastim on the following day of chemotherapy93 (56.7) Use pegfilgrastim on the following day of chemotherapy. I administer chemotherapy one day later of the next cycle, and use pegfilgrastim on the following day of chemotherapy8 (4.9) Do not use pegfilgrastim61 (37.2)Q21.What explanation or suggestion do you provide for bone pain, an adverse drug reaction, in the use of G-CSFs? (*N* = 187) Do not explain about adverse events of G-CSFs to a patient34 (18.2) Have a medical examination in the occurrence of bone pain67 (35.8) Prescribe oral NSAIDs in advance of the occurrence of bone pain85 (45.5) Prescribe oral antihistaminic drugs in advance in the occurrence of bone pain1 (0.5)Q22. Are G-CSFs used as primary prophylaxis at your institute? (*N* = 293) We used G-CSFs only during chemotherapy aimed at the symptom palliation39 (13.3) We used G-CSFs only during chemotherapy aimed at achieving a cure or prolonging survival time162 (55.3) We do not use G-CSFs as primary prophylaxis92 (31.4)*G-CSF* Granulocyte-Colony Stimulating Factor, *NSAIDs* Non-Steroidal Anti-Inflammatory Drugs

When asked "what explanation or suggestion do you provide for bone pain, an adverse drug reaction, in the use of G-CSFs?", the most common response (45.5%, *n* = 85) was "I will suggest prescribing oral NSAIDs in advance of the occurrence of bone pain" (Table [7](#Tab7){ref-type="table"}).

Discussion {#Sec9}
==========

In this questionnaire survey study of pharmacists engaged in cancer treatment nationwide, answers were obtained from 301 respondents. To our knowledge, the present study is the first and largest questionnaire regarding G-CSFs guidelines in Japan. Of all respondents, 82.4% were certified, accredited, or senior pharmacists in the field of cancer and palliative care; thus, responses were obtained from pharmacists who are mostly involved in cancer treatment across Japan, suggesting that the findings reflect the current use of G-CSFs at cancer treatment specialty hospitals throughout Japan.

User penetration rate and compliance are both important items for the evaluation of clinical practice guidelines. The penetration rate of the guideline was evaluated by the responses to question number 9. In this survey, 75.7% of participants recognized the availability of the JSCO guidelines on the web, thus indicating that the guidelines are widely accepted. In a prospective observational study conducted in Iran, 63.7% of prescriptions are in compliance with ASCO guidelines \[[@CR6]\]. A typical German sample survey reported that 85.1% of physicians adhere to G-CSF EORTC guidelines \[[@CR7]\]. Our current results support these previous findings. The high usability of the guidelines was demonstrated by the observation that 98.0% of the respondents answered that the guidelines are "useful for the work of pharmacists" and 51.5% replied that the guidelines are "referred in the work of pharmacists" (Table [3](#Tab3){ref-type="table"}). The usefulness of these guidelines as work guidelines for pharmacists was indicated by the observations that 98.0% reported the guidelines to be \"beneficial to the work of pharmacists\" and that 51.5% indicated that the guidelines are \"being referred to in the pharmacist\'s work\" (Table [3](#Tab3){ref-type="table"}). However, many respondents reported that \"there are differences from the pharmacist\'s work\" (58.4%), citing "prophylactic administration" as the reason for these differences. This is because the experience of PEGylated long-acting G-CSFs since their introduction in Japan in 2014 is inadequate and there is a large gap between clinical practice and the current guidelines. The second most frequent answer was that \"Pharmacists are not involved in the administration of G-CSFs\". In general, patient characteristics (age, complications, and general condition) are also important considerations in cancer chemotherapy regimens and help to determine whether G-CSFs are used. Therefore, in many cases, the clinical judgment of the physicians may be given priority (Table [3](#Tab3){ref-type="table"}). However, aggressive drug therapy should be under the guidance of a pharmacist. Pharmacists have knowledge regarding pharmaceutical science not only for anticancer drugs but also for general medicine. Therefore, it is important for cancer board-certified pharmacists to be included in discussions with doctors and medical staff regarding hospitalized and outpatient cancer patients. In addition, it is useful to periodically survey the actual clinical situation and to provide feedback to doctors on the proper use of G-CSFs.

Both national and international guidelines recommend the use of primary prophylaxis for cancer chemotherapy regimens with an FN incidence rate \> 20% \[[@CR3]--[@CR6]\]. When the cancer chemotherapy regimen (TC therapy for breast cancer) had an FN incidence rate \> 20%, it was highly likely that the pharmacist would propose the use of primary prophylactic G-CSFs (29.7%) (Table [4](#Tab4){ref-type="table"}). In contrast, the use of primary prophylactic G-CSFs was low (0.5% and 12.6%, respectively) in cancer chemotherapy regimens including cisplatin and S-1 therapy for gastric cancer and FOLFOXIRI therapy for colorectal cancer with FN incidence rates below 20% (Table [4](#Tab4){ref-type="table"}). As mentioned above, more pharmacists were likely to suggest the primary prophylactic administration of G-CSFs according to the treatment strategy recommended by the JSCO guidelines. In contrast, the response differed with respect to the secondary prophylactic administration of G-CSFs (Table [5](#Tab5){ref-type="table"}). This difference is likely because the JSCO guidelines' recommended grade for the secondary prophylactic administration of G-CSFs is \"C2 (the evidence is not known clearly)\". As indicated above, the use of G-CSFs as a secondary prophylactic should be decided in individual patients.

The collection rate of questionnaires is one of the factors used to evaluate the reliability of the results. However, we failed to determine the collection rate in this survey. This is because we requested participation from five academic societies whose expert pharmacists engaged mainly in cancer treatment; among them, four societies (JSPHCS, JSPO, JPPS, and JSCO) directly asked their members to participate via e-mail. However, the questionnaire was linked to a members-only website of the JSHP because e-mail distribution was difficult for this society. Therefore, the collection rate was not calculated because the total number of responses requested was uncertain.

Conclusions {#Sec10}
===========

The results of this questionnaire survey indicate that the guidelines on the proper use of G-CSFs issued by the JSCO have been widely accepted among pharmacists and are very useful. However, some negative opinions were observed. While clinical practice guidelines are generally revised every 3 years \[[@CR8]\], it may be necessary to periodically revise these guidelines owing to the introduction of new anticancer drug therapy and long-acting G-CSFs.
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